Orbital Therapeutics launches to advance new frontiers of science

Based in Cambridge, Massachusetts, USA, Orbital Therapeutics launched today with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

Terms of the financing are not being disclosed at this time, but it was led by ARCH Venture Partners (with co-founders/BOD members Kristina Burow and Carol Suh), with participation from a16z Bio + Health (Vineeta Agarwala named to BOD) and Newpath Partners.

“The breakthroughs in RNA therapeutics over the last decade have been remarkable achievements by the biopharmaceutical industry, with several approved products for a range of diseases and many more in development. This frontier of science represents the future of medicine, and we are just beginning to realize the full breadth of its applications in treating a wide range of serious diseases,” said John Maraganore, Orbital co-founder and chairman of the board of directors. “Orbital Therapeutics has a unique opportunity to integrate and apply a spectrum of innovative RNA technologies to advance a portfolio that could dramatically expand the potential of today’s RNA therapeutic approaches,” he added.